MARKET

KURA

KURA

Kura Oncology Inc
NASDAQ
14.70
-0.16
-1.08%
After Hours: 14.70 0 0.00% 16:02 11/28 EST
OPEN
14.71
PREV CLOSE
14.86
HIGH
15.18
LOW
14.65
VOLUME
511.72K
TURNOVER
0
52 WEEK HIGH
19.93
52 WEEK LOW
10.41
MARKET CAP
1.00B
P/E (TTM)
-7.2360
1D
5D
1M
3M
1Y
5Y
Kura Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D....
GlobeNewswire · 6d ago
Wall Street Analysts Think Kura Oncology (KURA) Could Surge 116%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 115.6% in Kura Oncology (KURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might tra...
Zacks · 11/14 14:55
Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting
Abstract featuring updated data from KOMET-001 trial of ziftomenib accepted for oral presentation on December 10, 2022SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to r...
GlobeNewswire · 11/03 13:00
Kura Oncology rises on $25M equity investment from Bristol Myers
Seekingalpha · 11/03 12:33
Recap: Kura Oncology Q3 Earnings
Benzinga · 11/03 12:21
Kura Oncology GAAP EPS of -$0.53 beats by $0.03
Seekingalpha · 11/03 11:59
BRIEF-Kura Oncology Inc Reports Quarterly Loss Per Share Of $0.53
Reuters · 11/03 11:49
Kura Oncology's Q3 Net Loss Widens
Kura Oncology's Q3 Net Loss Widens
MT Newswires · 11/03 11:38
More
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company’s segment is engaged in discovery and development of medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. It is developing its product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and hematologic indications. It is developing KO-539, a small molecule inhibitor of the Lysine K-specific Methyltransferase 2A (KMT2A) interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The Company is developing orally available, small molecule compounds that inhibit the interaction between the proteins menin and MLL for the treatment of MLL-rearranged (MML-r) leukemias, a genetically-defined subset of approximately two forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic.

Webull offers kinds of Kura Oncology Inc stock information, including NASDAQ:KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.